Stocks and InvestingStocks and Investing
Fri, December 15, 2023
Thu, December 14, 2023
Wed, December 13, 2023

Bradley Canino Upgraded (CCCC) to Strong Buy and Increased Target to $12 on, Dec 13th, 2023


Published on 2024-10-28 07:58:58 - WOPRAI, Bradley Canino
  Print publication without navigation


Bradley Canino of Stifel, Upgraded "C4 Therapeutics, Inc." (CCCC) to Strong Buy and Increased Target from $2 to $12 on, Dec 13th, 2023.

Bradley has made no other calls on CCCC in the last 4 months.



There are 4 other peers that have a rating on CCCC. Out of the 4 peers that are also analyzing CCCC, 2 agree with Bradley's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Terence Flynn of "Morgan Stanley" Upgraded from Sell to Hold and Decreased Target to $1 on, Monday, November 6th, 2023
  • Chi Fong of "B of A Securities" Maintained at Hold with Decreased Target to $2 on, Monday, October 9th, 2023


These are the ratings of the 2 analyists that currently disagree with Bradley


  • Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $16 on, Friday, November 3rd, 2023
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Thursday, November 2nd, 2023